文献速递肝肾功能剂量调整治疗药物监测与药物基因组学

加速静脉-静脉血液滤过期间万古霉素的清除与药代动力学

Vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration.
PubMed 文献 · Pharmacotherapy · 2023-10-16

该研究纳入18例接受万古霉素和加速静脉-静脉血液滤过(AVVH)的危重成人,通过单室药代动力学分析描述万古霉素在AVVH期间的清除和药代动力学参数,发现AVVH显著清除万古霉素,需在AVVH结束后补充给药以维持目标谷浓度,并推荐进行治疗药物监测。

要点

  • AVVH使万古霉素浓度降低29.8%,清除速率每小时3.4%。
  • AVVH期间万古霉素半衰期为17.6小时,AUC为171.7 mg*h/L。
  • AVVH结束后需补充万古霉素1000 mg以维持谷浓度≥15 mg/L。

核心结论

  • AVVH显著清除万古霉素,需在AVVH结束后补充给药以维持目标血清浓度。
  • 推荐对接受AVVH的患者进行万古霉素治疗药物监测。

研究设计与样本

  • 研究纳入18例接受万古霉素和AVVH的危重成人。
  • 在AVVH前4小时内和AVVH后2-6小时采集万古霉素血清浓度,采用单室药代动力学分析。
  • 连续数据以中位数(四分位距[IQR])表示,分类数据以百分比表示。

主要发现

  • AVVH effluent rate中位数为39.3 mL/kg/h(IQR 35.5-48 mL/kg/h),持续时间9小时(IQR 8-9.75小时)。
  • AVVH使万古霉素浓度降低29.8%(IQR 24.9%-35.9%),清除速率每小时3.4%(IQR 3.1%-4.3%)。
  • 万古霉素消除速率常数为0.039 h-1(IQR 0.036-0.053 h-1),半衰期为17.6小时(IQR 13.1-18.8小时)。
  • AVVH期间AUC为171.7 mg*h/L(IQR 149.1-190 mg*h/L)。
  • 10例患者的分布容积为1 L/kg(IQR 0.73-1.1 L/kg)。

临床怎么用

  • 对接受AVVH的危重患者,应在AVVH结束后补充万古霉素剂量以维持谷浓度≥15 mg/L。
  • 建议对AVVH患者进行万古霉素血清浓度监测以指导剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vancomycin pharmacokinetics are affected by renal replacement therapy and physiologic changes in critically ill patients. Literature regarding vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration (AVVH), a form of prolonged intermittent renal replacement therapy, is limited. OBJECTIVE: To describe the removal and pharmacokinetics of vancomycin during AVVH. METHODS: Eighteen critically ill adults receiving vancomycin and AVVH were included. Vancomycin serum concentrations were obtained within 4 h before and 2-6 h after the AVVH session. Patients' serum concentrations were plotted against time, and individual pharmacokinetic parameters were determined by a one-compartmental analysis. Continuous data are reported as a median (interquartile range [IQR]) and categorical data as a percentage. RESULTS: The median AVVH effluent rate was 39.3 mL/kg/h (IQR 35.5-48 mL/kg/h) for a duration of 9 h (IQR 8-9.75 h). AVVH decreased vancomycin concentrations by 29.8% (IQR 24.9%-35.9%), at a rate of 3.4% per hour (IQR 3.1%-4.3% per hour) of AVVH. The vancomycin elimination rate constant and half-life were 0.039 h-1 (IQR 0.036-0.053 h-1 ) and 17.6 h (IQR 13.1-18.8 h), respectively. The area under the curve during AVVH was 171.7 mg*h/L (IQR 149.1-190 mg*h/L). The volume of distribution in 10 patients was 1 L/kg (IQR 0.73-1.1 L/kg). After AVVH, vancomycin 1000 mg (IQR 750-1000 mg) was needed to maintain a serum trough concentration ≥15 mg/L. CONCLUSION: Vancomycin is significantly removed by AVVH, which requires supplemental dosing after completion of the AVVH session to maintain desired serum concentrations. Therapeutic drug monitoring of vancomycin serum concentrations is recommended for patients undergoing AVVH.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Lopez ND, Griggs M, Sin JH, et al. Vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration. Pharmacotherapy. 2023. PMID: 37798109. doi:10.1002/phar.2885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。